Breast Surgery Practice Questions

Q: BRCA-1 positive women have what percentage increased risk of breast carcinoma?

60%. **Explanation:** The correct answer is **60% (Option D)**. BRCA1 and BRCA2 are tumor suppressor genes involved in DNA repair via homologous recombination. Mutations in these genes significantly elevate the lifetime risk of developing breast and ovarian cancers compared to the general population (whose lifetime risk is approximately 12%). * **BRCA1:** Carries a lifetime breast cancer risk of approximately **60% to 80%**. It is also associated with a 40% risk of ovarian cancer and a higher prevalence of "Triple Negative" (ER/PR/HER2 negative) breast cancers. * **BRCA2:** Carries a slightly lower lifetime breast cancer risk of approximately **45% to 55%** and an ovarian cancer risk of about 20%. It is more commonly associated with male breast cancer. **Analysis of Incorrect Options:** * **Options A & B (10-20%):** These percentages are too low. While 10% of all breast cancers are hereditary, the individual risk for a mutation carrier is much higher. * **Option C (40%):** This is closer to the risk associated with BRCA2 or the ovarian cancer risk for BRCA1, but underestimates the penetrance for breast carcinoma in BRCA1 carriers. **High-Yield Clinical Pearls for NEET-PG:** 1. **Surveillance:** For BRCA-positive women, annual screening with **Contrast-Enhanced MRI** (starting at age 25) and Mammography (starting at age 30) is recommended. 2. **Prophylaxis:** Bilateral Salpingo-oophorectomy (BSO) reduces the risk of ovarian cancer by 90% and breast cancer by 50% if performed pre-menopausally. 3. **Molecular Subtype:** BRCA1 is most frequently associated with **Medullary Carcinoma** and Basal-like (Triple Negative) subtypes. 4. **Treatment:** **PARP inhibitors** (e.g., Olaparib) are specifically effective in BRCA-mutated cancers due to "synthetic lethality."

Q: A patient presents with a 4 cm carcinoma of the breast with skin ulceration involving the nipple. On palpation, axillary lymph nodes are positive. What is the most appropriate management?

Modified radical mastectomy. ### Explanation **1. Why Modified Radical Mastectomy (MRM) is the Correct Choice:** The patient presents with a **4 cm tumor** and **skin ulceration**, which classifies the tumor as **T4b** according to the TNM staging system. The presence of palpable axillary lymph nodes indicates **N1** status. This combination (T4b N1) signifies **Stage IIIB (Locally Advanced Breast Cancer - LABC)**. The standard surgical management for LABC, where breast conservation is contraindicated due to skin involvement and tumor size, is **Modified Radical Mastectomy (MRM)**. MRM involves the removal of the entire breast tissue (including the nipple-areola complex and involved skin) along with a Level I and II axillary lymph node dissection, while preserving the pectoralis major muscle. **2. Why Other Options are Incorrect:** * **A. Breast Conserving Procedure (BCP):** BCP is contraindicated here because skin ulceration (T4) and involvement of the nipple-areola complex make it impossible to achieve negative margins while maintaining cosmesis. * **B. Simple Mastectomy:** This procedure removes the breast but spares the axillary nodes. Since this patient has clinically positive nodes, an axillary clearance (part of MRM) is mandatory. * **C. Palliative Treatment:** This is reserved for Stage IV (metastatic) disease. Locally advanced breast cancer (Stage III) is treated with curative intent using a multimodality approach (Surgery, Chemotherapy, and Radiotherapy). **3. NEET-PG High-Yield Pearls:** * **T4 staging:** T4a (Chest wall), T4b (Skin edema/Peau d'orange/Ulceration), T4c (Both), T4d (Inflammatory carcinoma). * **MRM vs. Radical (Halsted) Mastectomy:** MRM preserves the pectoralis major; Halsted removes it. MRM is the current gold standard for operable breast cancer. * **LABC Protocol:** In modern practice, these patients often receive **Neoadjuvant Chemotherapy (NACT)** first to downstage the tumor, followed by MRM and radiotherapy.

Q: Halstead's mastectomy is defined as which of the following?

Radical mastectomy. **Explanation:** **Halsted’s Mastectomy**, also known as **Radical Mastectomy (RM)**, was the gold standard for breast cancer treatment for decades. It is defined by the en bloc removal of the entire breast tissue, the overlying skin, both the **Pectoralis major and Pectoralis minor** muscles, and all three levels (I, II, and III) of axillary lymph nodes. The procedure is based on the Halstedian theory that cancer spreads in a centrifugal, orderly fashion. **Analysis of Options:** * **Option A (Simple Mastectomy):** This involves the removal of the entire breast tissue and nipple-areola complex but **spares** the axillary lymph nodes and pectoral muscles. * **Option B (Wide Local Excision):** This is a breast-conserving surgery (BCS) where only the tumor and a margin of healthy tissue are removed, preserving the breast. * **Option D (Modified Radical Mastectomy - MRM):** This is the current standard. Unlike Halsted’s, MRM **preserves the Pectoralis major muscle**. The most common variant is the **Auchincloss** (preserves both muscles) or **Patey** (removes Pectoralis minor to access Level III nodes). **High-Yield Clinical Pearls for NEET-PG:** * **Structures Preserved in Halsted’s:** Only the nerves (Long thoracic and Thoracodorsal) and major vessels are ideally spared, though historically, morbidity was high. * **Patey’s MRM:** Removes Pectoralis minor; **Auchincloss MRM:** Preserves Pectoralis minor. * **Madden’s MRM:** Preserves both pectoral muscles and is the most frequently performed version today. * **Indication:** Radical mastectomy is rarely performed today, reserved only for cases where the tumor involves the Pectoralis major muscle.

Q: What is defined as the sentinel lymph node?

The primary lymph node draining the tumor.. ### Explanation **1. Why Option A is Correct:** The **Sentinel Lymph Node (SLN)** is defined as the first lymph node (or group of nodes) in a regional lymphatic basin that receives direct lymphatic drainage from a primary tumor. The underlying medical concept is the **"Sentinel Node Hypothesis,"** which posits that if the tumor were to spread via the lymphatic system, the sentinel node would be the first to be seeded. If the SLN is negative for malignancy, there is a high probability (usually >95%) that the remaining nodes in that basin are also negative, allowing surgeons to avoid unnecessary axillary lymph node dissection (ALND). **2. Why the Other Options are Incorrect:** * **Option B:** The first node excised during a Modified Radical Mastectomy (MRM) is irrelevant to the definition. In a standard MRM, an axillary clearance (Levels I and II) is performed regardless of which node is "first" removed. SLN biopsy is typically done *instead* of an MRM's axillary clearance in early-stage breast cancer. * **Option C:** Proximity does not equal drainage. While the SLN is often near the tumor, the definition is strictly based on **lymphatic flow**, not anatomical distance. A node further away may be the "sentinel" if the lymphatic channels bypass closer nodes (skip metastasis is rare but possible). **3. Clinical Pearls for NEET-PG:** * **Identification:** Usually performed using **Technetium-99m labeled sulfur colloid** (radioactive tracer) and/or **Isosulfan/Methylene Blue dye**. * **Indications:** Clinically node-negative (cN0) early-stage breast cancer (T1-T2). * **Contraindications:** Inflammatory breast cancer, clinically palpable axillary nodes, or biopsy-proven positive nodes. * **Success Criteria:** The "Hot and Blue" rule—nodes that are radioactive (detected by a gamma probe) or stained blue are considered sentinel nodes.

Q: Ixabepilone is used in the treatment of which of the following conditions?

Breast carcinoma. **Explanation:** **Ixabepilone** is a semi-synthetic analog of epothilone B, a novel class of cytotoxic agents. Its primary mechanism of action involves binding directly to **β-tubulin subunits**, which stabilizes microtubules and induces cell cycle arrest at the G2-M phase, leading to apoptosis. Unlike taxanes, ixabepilone retains activity in cells that overexpress multidrug resistance (P-glycoprotein) or have specific tubulin mutations. **Why Breast Carcinoma is Correct:** Ixabepilone is FDA-approved specifically for the treatment of **metastatic or locally advanced breast cancer**. It is particularly indicated for patients who have developed resistance to anthracyclines and taxanes. It can be used as monotherapy or in combination with Capecitabine. **Why Other Options are Incorrect:** * **Melanoma:** While various microtubule inhibitors have been studied, the mainstay of systemic therapy for melanoma involves immunotherapy (Checkpoint inhibitors) and targeted therapy (BRAF/MEK inhibitors). * **Oat cell/Small cell carcinoma lung:** These are typically treated with platinum-based regimens (e.g., Cisplatin + Etoposide). While taxanes are used in non-small cell lung cancer (NSCLC), Ixabepilone is not a standard treatment for small cell variants. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** Epothilone (Microtubule stabilizer). * **Indication:** Triple-negative breast cancer (TNBC) and taxane-resistant metastatic breast cancer. * **Side Effects:** Peripheral neuropathy (most common dose-limiting toxicity) and myelosuppression (neutropenia). * **Advantage:** It has a lower affinity for the P-glycoprotein efflux pump compared to Paclitaxel, making it effective in drug-resistant tumors.

Q: A 43-year-old man presents with signs and symptoms of peritonitis in the right lower quadrant. The clinical impression and supportive data suggest acute appendicitis. At exploration, however, a tumor is found; frozen section suggests carcinoid features. A 2.5-cm tumor is located at the base of the appendix. What is the most appropriate surgical procedure for this tumor?

Right hemicolectomy. **Explanation:** The management of appendiceal carcinoid tumors (neuroendocrine tumors) is primarily determined by the **size** and **location** of the tumor. **Why Right Hemicolectomy is correct:** While most appendiceal carcinoids are small and managed by simple appendectomy, a **Right Hemicolectomy** is indicated in the following high-risk scenarios: 1. **Size >2 cm:** Tumors larger than 2 cm have a significantly higher risk of nodal metastasis (up to 30%). 2. **Location at the Base:** Tumors at the base of the appendix can involve the cecum or compromise the surgical margin during a simple appendectomy. 3. **Invasion:** Involvement of the mesoappendix (especially >3mm), lymphovascular invasion, or high-grade histology. In this case, the tumor is **2.5 cm** and located at the **base**, making a right hemicolectomy the standard of care to ensure oncological clearance and lymph node dissection. **Why incorrect options are wrong:** * **Appendectomy:** Only sufficient for tumors ** 2 cm. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site** of carcinoid tumor in the GI tract: **Appendix** (overall), but **Small Intestine** (specifically ileum) is often cited as the most common site for *symptomatic* or larger carcinoids. * **Most common location** within the appendix: **Tip** (70%). * **Carcinoid Syndrome:** Rarely occurs with appendiceal carcinoids unless there are extensive liver metastases. * **Rule of Thumb:** 2 cm = Right Hemicolectomy; 1–2 cm = Appendectomy (unless high-risk features are present).

Q: What is true about leiomyosarcoma of the breast?

It is well encapsulated.. **Leiomyosarcoma of the breast** is an extremely rare primary stromal malignancy, accounting for less than 0.1% of all breast cancers. Unlike common breast carcinomas, it originates from the smooth muscle cells of the nipple-areolar complex or blood vessel walls. ### **Explanation of Options** * **Why B is Correct:** Leiomyosarcoma typically presents as a slow-growing, firm, and **well-encapsulated** or well-circumscribed mass. On imaging and gross pathology, it often mimics benign lesions like fibroadenomas because of this distinct encapsulation, which can lead to a delay in diagnosis. * **Why A is Incorrect:** Like most sarcomas, leiomyosarcoma spreads primarily via the **hematogenous route** (bloodstream) rather than the lymphatic system. Axillary lymph node involvement is exceedingly rare; therefore, routine axillary dissection is not indicated. * **Why C is Incorrect:** These tumors have a high risk of **local recurrence** and potential distant metastasis (commonly to the lungs). Long-term follow-up is essential to monitor for recurrence. * **Why D is Incorrect:** The mainstay of treatment is **Wide Local Excision (WLE)** with negative margins (at least 1 cm). Mastectomy is reserved only for very large tumors or cases where clear margins cannot be achieved with breast-conserving surgery. ### **NEET-PG High-Yield Pearls** * **Origin:** Most commonly arises from the subareolar region (smooth muscle of the nipple). * **Diagnosis:** Requires IHC (Immunohistochemistry). They are typically **SMA (Smooth Muscle Actin) positive** and Desmin positive, but negative for cytokeratins and S-100. * **Treatment Rule:** Sarcomas of the breast = Wide Local Excision + No Axillary Dissection (unless nodes are clinically palpable). * **Prognosis:** Generally better than other breast sarcomas if the tumor is small and completely excised.

Q: A 40-year-old female presents with a 4 cm breast lump involving the skin and a mobile, palpable axillary lymph node. FNAC of the lesion shows intraductal carcinoma. What is the initial management for this patient?

Neoadjuvant chemotherapy. ### Explanation **Correct Answer: B. Neoadjuvant Chemotherapy (NACT)** The patient presents with a 4 cm breast lump involving the skin (T4b) and a mobile axillary lymph node (N1). According to the TNM staging system, any skin involvement (ulceration or edema/peau d'orange) classifies the tumor as **Stage IIIB (Locally Advanced Breast Cancer - LABC)**. The standard of care for LABC is **Neoadjuvant Chemotherapy (NACT)**. The primary goals are to downstage the tumor, increase the likelihood of breast-conserving surgery (BCS), and treat micrometastatic disease early. Surgery is performed only after the tumor has responded to chemotherapy. **Why other options are incorrect:** * **C & D (MRM and Simple Mastectomy):** Upfront surgery is contraindicated in LABC (Stage III). Operating on a tumor with skin involvement without prior downstaging often leads to positive margins and high recurrence rates. * **A (Radiotherapy):** Radiotherapy is a component of multimodality treatment but is typically administered *after* surgery (Adjuvant) to reduce local recurrence, not as the initial primary treatment. **Clinical Pearls for NEET-PG:** * **LABC Definition:** Includes T3 (>5cm), T4 (skin/chest wall involvement), or N2/N3 nodal status. * **T4 categories:** T4a (Chest wall), T4b (Skin: ulceration/peau d'orange), T4c (Both), T4d (Inflammatory carcinoma). * **Sequence of Management in LABC:** NACT → Surgery (MRM or BCS) → Adjuvant Radiotherapy → Hormonal/Targeted therapy (if indicated). * **Dimpling vs. Peau d'orange:** Dimpling is due to involvement of **Cooper’s ligaments** (T2/T3), whereas peau d'orange is due to **subdermal lymphatic obstruction** (T4).

Question 1

BRCA-1 positive women have what percentage increased risk of breast carcinoma?

Accepted Answer

60%

Answer

10%

Answer

20%

Answer

40%

Question 2

A patient presents with a 4 cm carcinoma of the breast with skin ulceration involving the nipple. On palpation, axillary lymph nodes are positive. What is the most appropriate management?

Accepted Answer

Modified radical mastectomy

Answer

Breast conserving procedure

Answer

Simple mastectomy

Answer

Palliative treatment

Question 3

Halstead's mastectomy is defined as which of the following?

Accepted Answer

Radical mastectomy

Answer

Simple mastectomy

Answer

Wide local excision

Answer

Modified radical mastectomy

Question 4

What is defined as the sentinel lymph node?

Accepted Answer

The primary lymph node draining the tumor.

Answer

The first lymph node excised during a modified radical mastectomy.

Answer

The lymph node nearest to the tumor.

Answer

None of the above.

Question 5

Which of the following structures is spared in a modified radical mastectomy?

Accepted Answer

Pectoralis major

Answer

Pectoralis minor

Answer

Axillary lymph nodes

Answer

Nipple

Question 6

Ixabepilone is used in the treatment of which of the following conditions?

Accepted Answer

Breast carcinoma

Answer

Melanoma

Answer

Oat cell carcinoma

Answer

Small cell carcinoma lung

Question 7

A 43-year-old man presents with signs and symptoms of peritonitis in the right lower quadrant. The clinical impression and supportive data suggest acute appendicitis. At exploration, however, a tumor is found; frozen section suggests carcinoid features. A 2.5-cm tumor is located at the base of the appendix. What is the most appropriate surgical procedure for this tumor?

Accepted Answer

Right hemicolectomy

Answer

Appendectomy

Answer

Segmental ileal resection

Answer

Cecectomy

Question 8

What is true about leiomyosarcoma of the breast?

Accepted Answer

It is well encapsulated.

Answer

Axillary lymph node dissection is mandatory.

Answer

Follow-up is not required.

Answer

Mastectomy is the mainstay of treatment.

Question 9

Which of the following statements about breast cancer is incorrect?

Accepted Answer

Breast cancer incidence increases with prolonged breastfeeding.

Answer

Having an affected sibling is a risk factor for breast cancer.

Answer

Paget's disease of the nipple is a type of intraductal carcinoma.

Answer

Breast cancer is common in elderly nulliparous women.

Question 10

A 40-year-old female presents with a 4 cm breast lump involving the skin and a mobile, palpable axillary lymph node. FNAC of the lesion shows intraductal carcinoma. What is the initial management for this patient?

Accepted Answer

Neoadjuvant chemotherapy

Answer

Radiotherapy

Answer

Modified radical mastectomy

Answer

Simple mastectomy

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?